A key goal of aging research is to understand mechanisms underlying healthy aging and use them to develop 9 methods to promote the human healthspan. One approach is to identify gene regulations differentiating 10 healthy aging from aging in the general population (i.e., "common" aging). In this study, we leveraged 11 GTEx (Genotype-Tissue Expression) project data to investigate "healthy" and "common" aging in humans 12 and their interconnection with diseases.
Introduction 1
Human life expectancy has increased by more than 30 years in the past 165 years in developed countries 2 like the US (Christensen et al. 2009 ). By 2050, two billion of the estimated nine billion people on earth will 3 be older than 60 (Burch et al. 2014 ). Aging is the major risk factor for many age-related diseases, including 4 cancers, metabolic diseases, neurodegenerative diseases, and cardiovascular diseases (Johnson et al. 2015 ).
5
The prevalence of age-related comorbidity is high, as over 80% of the elderly population having at least 6 one chronic diseases (CDC 2011) . Helping this 80% of the aging population to live with improved health 7 condition has become a major task for human aging and geroscience research, which can have major impact 8 to socioeconomics and humanity. 9 10 It remains elusive why the fortunate 20% of individuals above 65 years of age can live without any major 11 health issues while the rest majority have to endure one or more chronic course of illness. Since very long-12 lived individuals (e.g., centenarians) tend to have a lower incidence of chronic illness than those in their 13 80s and 90s (Kheirbek et al. 2017) , and longevity is heritable with an estimated heritability around 25%, 14 this suggests that healthy aging is unlikely a random event, but that there are underlying biological 15 mechanisms favorably interplayed with certain environmental factors. A key goal of aging and geroscience 16 research is to reveal these mechanisms to identify effective methods to promote the human healthspan. 17 
18
Multiple approaches have been explored to achieve this goal. For example, studies have been performed to 19 identify genetic factors associated with longevity which identified a few genes (such as APOE and FOXO3) 20 that are considered reproducible (Yashin et al. 2018) . It is somewhat surprising to see that many disease 21 risk alleles' occurrences are not significantly different in centenarians versus control population, making it 22 a reasonable hypothesis that some protective factors exist to counter the deleterious effect of the disease 23 risk genes (Bergman et al. 2007 ). In addition to searching for these protective genetic factors, people have 24 also hypothesized that healthy aging individuals maintain a favorable epigenetic profile and optimal gene 25 expression that are critical for longevity and disease prevention (Brooks-Wilson 2013). However, the exact 1 epigenetic and gene expression profiles defining a healthy aging are still unknown. 2 3 Gene expression and other types of "omics" data have been widely used to study the process of aging 4 (Edwards et (2013) . In addition to gene expression, epigenetic clock of aging has also been developed based on 12 DNA-methylation markers (Horvath and Raj 2018) . These recent studies provide support that gene 13 expression and epigenetic regulations can inform our understanding of human aging. 14 15 Despite recent developments in transcriptomic and epigenetic aging research, limited studies have focused 16 on understanding the processes involved in healthy human aging. To investigate how healthy aging is 17 different from aging in the general population at a systems level, one approach is to profile tissues from a 18 healthy aging cohort and compare these to the common aging population, to identify gene regulations 19 specific to the healthy aging. However, obtaining essential tissues from healthy individuals is challenging 20 for ethical and practical reasons. On the other hand, several large-scale human genomic datasets are 21 available and can be repurposed for aging research. Here, we leveraged GTEx data (Consortium et al. 2017) 22 to investigate the difference between "healthy" and "common" aging in humans and study their connection 23 with diseases using a transcriptomic analysis. 24 
25
We selected GTEx donors who were not annotated with diseases to approximate a "healthy" cohort. We 26 calculated age-associated gene expressions in this "healthy" cohort and compared it to age-associated genes 5 from the "common" cohort which included all GTEx donors. We also compared the "healthy" and 1 "common" aging gene expression with various disease-associated gene expressions to elucidate the 2 relationships among "healthy" aging, "common" aging, and diseases.
3

Results
4
Data overview 5 We obtained gene expression and genotype data from the GTEx V7 release and examined 46 tissues with 6 over 80 samples per tissue type, for a total of 11,705 samples, covering 620 donors (Supplemental Table   7 S1, 2, Supplemental Fig. S1 ).
9
The GTEx data contained detailed information for each sample and donor, including the donor's age, post-10 mortem interval (PMI), RNA integrity number (RIN) and additional information. GTEx donor ages were 11 between 20 to 70 years, and donor PMI was defined as the time between death to the start of sample Table S3 ). We used the sample PMI for 15 majority of the tissues; while we used donor ischemia time for samples from 11 brain subregions, since 16 GTEx did not contain sample ischemic time information for them (see Methods). 17 
18
The influence of PMI on age-associated gene identification is tissue-specific 19 Previous studies reported that some genes' expression continued to change after death in a tissue-specific 20 manner (Ferreira et al. 2018) . As the majority of the GTEx samples were post-mortem samples, some gene 21 expression changes due to PMI could potentially interfere with our age-associated gene expression 22 identification. To ensure that our age-associated gene identification will not be confounded by PMI, we 23 started our analysis by evaluating the relationship between PMI and donor age. We observed a significant 24 positive Pearson correlation between PMI and chronological age in adipose, tibial artery, tibial nerve, 25 skeletal muscle and whole blood (the correlation coefficients were between 0.008 to 0.010, and the 1 Benjamini-Hochberg false discovery rate (FDR) ranged from 2.52×10 -7 to 2.77×10 -5 ). PMI showed no 2 correlation with age in other tissues including all brain subregions, pituitary and terminal ileum, etc. Fig. S3a and Table S4 ). In contrast, RIN was negatively associated with age in most tissues, 4 particularly in colon, arteries, esophagus and lung (Supplemental Fig. S3b and Table S4 ).
(Supplemental
6
To examine the influence of PMI on age-associated gene expression changes, we compared two linear 7 regression models. In the first model, we only adjusted gene expression with sex, RIN, three genotype-8 based principal components (PCs) and gene expression PCs (see methods). In the second model, PMI was 9 included as an extra covariate. For both regression models, we set FDR cut-off to 0.01 to select significant 10 associations between gene expressions and age.
12
Our results showed that correcting PMI had clear impact on age-associated gene identification in some 13 tissues (Supplemental Fig. S4 ). Overall, we observed decreased number of age-associated genes in most 14 tissues when we corrected for PMI ( Supplemental Table S5 ). This pattern was particularly apparent in 15 breast mammary, skin, whole blood, lung and adipose tissues. A few exceptions were prostate and minor 16 salivary gland, in which more age-associated genes were found after the PMI correction. In general, for the 17 46 tissue types we considered, tibial artery showed the largest number of genes associated with age (briefly 18 called as aging genes) (n=8,709), followed by aorta artery (n=5,826), skeletal muscle (n=4,444), nerve tibial 19 (n=3,619) and subcutaneous fat (n=3,812). In contrast, very few aging genes were identified from brain -20 spinal cord (n=0), brainsubstantia nigra (n=0), pituitary (n=1), small intestine -terminal ileum (n=1) and 21 liver (n=7) (Supplemental Table S5 ). The wide range and tissue specificity of the size of aging genes is 22 consistent with our previous findings (Yang et al. 2015 ).
24
GTEx human aging signatures reasonably recapitulated aging genes from other independent studies 25 To evaluate whether aging signatures derived from GTEx data were reproducible, we compared them to 26 age-associated gene lists from five independent studies covering the following tissues: brain ( Age-associated gene lists generated from GTEx showed a significant overlap with genes identified from 5 these independent studies. For example, in brain and lung tissues, more than 30% of our genes were found 6 overlapped with other studies, with p-values of 5.81×10 -176 and 4.32×10 -59 respectively (Supplemental 7   Table S6 ), suggesting the aging signatures from GTEx were comparable with the aging signatures from 8 other independent studies. 9 10 Interestingly, despite that fewer age-associated genes could be identified by PMI correction in four out of 11 the five tissues, we consistently observed an increase of the overlap between independently identified aging 12 genes and our aging genes in these four tissues, e.g., from 10.53% to 12.70% in blood, 29.30% to 37.04% 13 in lung (Supplemental Table S6 ), suggesting that the correction of PMI could help increase the 14 reproducibility and robustness of aging signature identification. 15 
16
Determining "common" and "healthy" aging signatures
17
A key goal of aging research is to study mechanisms underlying healthy aging and based on them to identify 18 effective methods to promote human healthspan. However, our understanding of healthy aging is rather 19 limited. Particularly, a clear understanding of healthy aging at the molecular level is yet to be established.
20
For example, it remains to be studied at a systems level how healthy aging is different from common aging, 21 as aging process is usually accompanied with various chronic diseases (Global Burden of Disease Study 22 2015). One approach to study this is to collect tissue samples from a healthy aging cohort to identify age-23 associated gene regulations, and compare with general aging population to determine regulations that are 24 unique to the healthy aging. By definition, a truly healthy individual does not die due to chronic diseases.
25
To obtain essential tissues (liver, brain, heart etc.) from these healthy individuals, it is only possible if such 26 donors experiences death due to some other cause, such as accidents, which could not be predicted. Prompt 8 tissue collection can therefore be challenging. On the other hand, evaluating existing human genomic data 1 and repurposing them for aging research represents a convenient alternative, although the apparent 2 limitation is that the original experiment was not ideally designed for studying aging and therefore might 3 not provide measurements on many age-related traits. Since GTEx cohort contained donors annotated with 4 and without chronic diseases, it represents a unique opportunity to allow us to understand the difference 5 between "common" vs. "healthy" aging at a transcriptome level. For each donor, GTEx recorded the 6 donor's medical condition for 21 disease categories, e.g., ischemic heart disease, cerebrovascular disease, 7 chronic respiratory disease, diabetes mellitus type II and hypertension. We mapped these disease categories 8 to their biologically relevant tissues, such as various lung diseases to the lung tissue; diabetes and obesity 9 to the adipose tissue. In addition, we required a tissue to have a relatively large number of aging genes, and 10 the sample size of disease donors to be relatively large (>20% of all tissue samples). Based on these criteria, 11 subcutaneous fat, tibial artery, aorta artery and lung tissues were selected for further study regarding the 12 difference between "healthy" and "common" aging.
14
Initially, we defined "common" aging signatures as gene expression changes associated with age in the 15 general GTEx cohort, for which we included all the donors regardless of their disease status ("common" 16 cohort). Since this "common" cohort contains individuals annotated with and without chronic diseases, we 17 used them to approximate the general aging population in the society. The "healthy" aging signature was 18 defined as gene expression changes associated with age in the GTEx cohort excluding individuals annotated 19 with tissue-specific diseases ("healthy" cohort). For example, for subcutaneous fat, the "common" aging 20 signatures were calculated from all subcutaneous fat (total n=385), while the "healthy" aging signatures 21 were identified from donors without type 2 diabetes and whose Body Mass Indexes (BMIs) were <30, 22 which resulted in 236 samples (Fig. 1a ). In tibial artery (total n=382), the "healthy" cohort (n=292) was 23 obtained from GTEx donors without ischemic heart disease/heart attack/acute coronary syndrome. In lung 24 (total n=379), the "healthy" cohort (n=257) was obtained from donors without chronic respiratory diseases, 25 asthma or pneumonia (details can be seen in Supplemental Table S7 ). A linear regression model was then 26 applied to identify aging genes in each of the aging cohorts (equation 2).
It is of note that the "healthy" cohort in this study is more defined at a "healthy" tissue-level rather than a 1 cohort of individuals free of any diseases. For instance, the "healthy" cohort extracted from subcutaneous 2 fat could contain individuals with ischemic heart disease, asthma or chronic obstructive pulmonary disease 3 (COPD). Although theoretically it is ideal to remove individuals annotated with any disease types to obtain 4 a better defined "healthy" cohort, this is not a good option with current GTEx data release since very few 5 samples would be left after this procedure, which could significantly reduce the statistical power of 6 identifying age-associated genes. For instance, only 65 out of 385 samples would remain for subcutaneous 7 fat, and 48 out of 379 samples would remain for lung tissue if we removed all the donors annotated with 8 one or more diseases. Due to this sample size limitation, we chose to approximate our "healthy" cohort in 9 such a tissue-specific way. subgroups. We therefore removed aorta artery from the DEG-related analysis ( Supplemental Table S7 ). We "common" aging signature identified from the "common" cohort, "healthy" aging signature from the "healthy" cohort, 4 and DEGs calculated between the "healthy" cohort and the "disease" cohort in subcutaneous fat. c,d,e Scatter plots 5 show 3 representative age-associated gene expression patterns in three gene sets (from top to bottom: "core-aging 1 Our results showed that DEGs from GTEx significantly overlapped with disease signatures from prior 2 independent studies in the corresponding tissues ( Supplementary Table S8 ). For example, Soronen et al. comparisons indicated that our separation of "healthy" and "disease" individuals based on the GTEx donor 13 health information for the corresponding tissue types was biologically meaningful. 14 
15
Characterizing "healthy" and "common" aging signatures suggests some "common" aging genes 16 could be driven by diseases while "healthy" aging signature contained some protective genes 17 To compare "healthy" and "common" aging signatures, we divided them into three groups: aging genes 18 only seen in the "common" cohort ("common-specific aging genes", CSAGs), aging genes only observed 19 in the "healthy" cohort ("healthy-specific aging genes", HSAGs), and common aging genes identified from 20 both cohorts ("core-aging genes", CAGs). In general, we observed a large overlap between "common" and 21 "healthy" aging signatures in all the four tissues we inspected. For example, in subcutaneous fat, 3,812 22 "common" aging genes overlapped with 2,366 "healthy" aging genes by 2,177 genes ( Fig. 1b and 23 Supplemental Table S7 ), suggesting that although "healthy" aging is different from "common" aging, they CSAGs, the expression of integrin subunit alpha X (ITGAX) was significantly positively correlated with 2 age in subcutaneous fat in the "common" cohort (FDR=7.12×10 -4 ), while its association with age was much 3 less significant in the "healthy" cohort (FDR=0.03) ( Fig. 1d) . ITGAX encodes the integrin alpha X chain 4 protein (also named CD11c), which forms a leukocyte-specific integrin when combined with the beta 2 5 chain (ITGB2). Previous studies reported that CD11c expression in adipose tissue significantly increased 6 in both diet-induced obesity mice and humans (Wu et al. 2010 ). This is consistent with our results as ITGAX 7 was up-regulated in GTEx adipose tissues of donors with high BMIs and type 2 diabetes ( Fig. 2d ). Since 8 this gene had a positive correlation with age in the "common" cohort but not so when disease individuals 9 were removed, it indicates that its association with age in the "common" cohort was partially driven by the 10 disease individuals. As can be seen in Fig. 1a , over 1,600 CSAGs were identified in the subcutaneous fat, 11 and more than 200 of them were disease DEGs, suggesting that many aging genes derived from the 12 "common" cohort could be partially driven by disease. In contrast, as an example of HSAGs, gene 13 expression changes of ELL-associated factor 2 (EAF2) showed strong up-regulation with age 14 (FDR=1.58×10 -3 ) in the "healthy" cohort ( Fig. 1e ), but to a less degree in the "common" cohort 15 (FDR=0.015). EAF2 gene was found to regulate DNA repair and provide protection to DNA damage in 
22
In addition to having different age-association for their gene expressions, we found that CAGs and CSAGs 23 had significant higher overlap with disease-associated DEGs compared to HSAGs. As shown for 24 subcutaneous fat (Fig. 1b) , 400 and 202 genes from CAGs and CSAGs were disease associated DEGs (p-25 values=5.40×10 -3 and 1.36×10 -32 , respectively, Supplemental Table S9 .). In contrast, only 17 disease DEGs 26 overlapped with HSAGs (p-value=0.78). Similarly, CAGs from tibial artery were specially enriched for its disease DEGs (p-value=9.73×10 -10 ), and lung CSAGs were also overrepresented in lung disease associated 1 DEGs (p-value=3.09×10 -11 ). While HSAGs were found much less significantly enriched for disease DEGs 2 in tibial artery (p-value=0.03) and lung (p-value=1.00).
4
The direction of aging gene expression is largely consistent with the regulation direction in age-5 related diseases 6 One key question in geroscience is to understand the underlying mechanisms why aging dramatically 7 increases the incidence of various age-related diseases. Since we had obtained aging signatures from both 8 "healthy" and "common" cohorts, and signatures associated with several diseases, we examined the 9 relationships between "healthy", "common" aging and disease. 10 
11
We compared different aging signatures with 7 disease signatures, 4 from previous independent studies 12 ( insulin resistance related, obesity related, CHD and COPD) and 3 from DEGs calculated from GTEx data.
13
We observed that most of the disease DEGs were not genes in our aging signatures (Supplemental Table   14 S10). Using insulin resistance/obesity related DEGs in subcutaneous fat as an example, over 60% of them 15 were not associated with age. Furthermore, as previously noticed, "healthy" aging was less enriched for 16 disease DEGs compared with "common" aging. For example, in subcutaneous fat, 36% of "common" aging 17 signatures were found as insulin resistance DEGs, while only 27% of "healthy" aging signatures were 18 insulin resistance DEGs (Fig. 2a ). 19 
20
Although disease and aging signatures were largely different, a substantial number of gene expression 21 regulations were common between them. We considered it interesting to test if age-associated gene 22 expression (particularly in the "healthy" aging) would have similar directions as the regulation changes in 23 disease conditions. We decided to focus on the "healthy" aging since the "common" aging cohort contained 24 disease individuals, therefore the "common" aging genes were not defined independently from disease-25 associated gene regulations. On the other hand, "healthy" aging genes were identified from the "healthy" 26 cohort, which were considered disjoint from the disease DEGs detected from the "disease" cohort. Our results showed that in most cases, the direction of aging gene regulation in "healthy" aging was largely 1 consistent with the direction of gene expression changes in disease (Fig. 2b&c ). Using FERM domain 2 containing 4B (FRMD4B) in subcutaneous fat as an example, it was an insulin resistance DEG (also a 3 disease DEG in our GTEx analysis). It is an inflammation-related gene whose expression was up-regulated 4 in the adipose tissue in insulin resistant compared to insulin sensitive group (Wiklund et al. 2016 ). Our 5 results also showed that the gene expression of FRMD4B was up-regulated with increasing age and in 6 disease condition. This consistency suggests that even under "healthy" aging condition, some genes' 7 regulation is towards a direction that transforms the tissue into a more disease-prone state.
9
While the direction of gene expression regulation is largely consistent between "healthy" and disease 10 signatures, some gene regulations showed opposite directions of regulation ( Fig. 2d ). For example, 11 malonyl-CoA-Acyl carrier protein transacylase (MCAT), a gene related to pathways like fatty acid 12 metabolism and mitochondrial fatty acid beta-oxidation, its gene expression was found negatively 13 correlated to plasma HDL levels (Ma et al. 2007 ). In GTEx data, MCAT showed a down-regulation in Difference in functional enrichment between "healthy" and "common" aging signatures 1 We investigated the function similarity and difference between "healthy" and "common" aging signatures 2 using DAVID tools (Dennis et al. 2003) . Genes were divided into up-regulated vs. down-regulated genes 3 with respect to age and were annotated separately ( Supplemental Table S11 ). Table S12 ). 14 
15
Genes up-regulated with age were enriched for a set of different functions compared with genes down-16 regulated with age ( Fig. 3 ). For example, CAGs in subcutaneous fat were characterized for response to 17 immune/defense/inflammatory, T cell receptor signaling pathway and chemokine signaling pathway, and 18 it was reported that aging is associated with increased T-cell chemokine expression (Chen et al. 2003 ). Up-19 regulated CAGs in tibial artery were enriched for similar functions as adipose tissue, in addition, they were 20 also found to be associated with intestinal immune network for IgA production, MHC protein complex and 21 various pathologies. Very few functions were found in up-regulated CSAGs and HSAGs, and they were 22 mostly associated with extracellular component (A full list of functional annotations is provided in 23 Supplemental Table S12 ). down-regulated genes separately. To visualize the results, we displayed the top 10 disease/traits that had 14 significant enrichment in at least one type of age-associated genes for each tissue in Fig. 4 . A total of 75 15 unique diseases/traits with significant overrepresented in down-regulated aging signatures, and 74 unique 1 diseases/traits with significant overrepresented in up-regulated aging signatures were displayed (Fig. 4 ).
2
We found that disease gene enrichment for "healthy" and "common" aging signatures varied in a tissue-3 specific manner. For the up-regulated aging genes, most of the significant disease enrichment was observed 4 in either CAGs or CSAGs and to a lesser degree in the HSAGs (Fig. 4a ). For example, in tibial artery,
5
CAGs were found to be strongly associated with multiple bowel diseases, including ulcerative colitis, 
9
For genes decreased with chronological age, we generally observed more significant overlaps with various 10 disease traits for all types of aging genes, including the HSAGs (Fig. 4b ). For example, in the tibial artery, 11 the HSAGs were significantly enriched for genes associated with hypertension (p-value=1.88×10 -3 ); but the 12 enrichment was not observed for the CAGs (p-value=0.82) or CSAGs (p-value=0.57). This is not totally 13 surprising for HSAGs, since down-regulation of such disease-associated gene expression could be 14 beneficial to the healthy aging. Overall, the disease gene enrichment analysis suggests differential 15 regulation of disease genes (fewer up-regulated genes while more down-regulation) with respect to 16 "common" and "healthy" aging.
17
Last but not least, we tested the enrichment of literature curated candidate human aging genes with respect 18 to "healthy" and "common" aging signatures. 307 candidate human age genes were downloaded from 19 GenAge (de Magalhaes and Toussaint 2004). We then calculated the overlap enrichment with three aging 20 gene sets (Table 1 ). Our results showed that CAGs in subcutaneous fat and aorta artery were enriched for 21 human aging genes from GenAge (p-value < 0.01), while neither the CSAGs or HSAGs were enriched for 22 them. 
1
We compared "core-aging genes", "common-specific aging genes" and "healthy-specific aging genes" from 2 subcutaneous fat, aorta artery, tibial artery and lung with human aging genes from GenAge. No. of background genes 3 was set as the number of all genes we used to calculate age-associated genes in each tissue; No. of GenAge contains 4 the number of overlapped genes between GenAge and our background genes vs. the total number of original GenAge 5 genes; p-value was calculated by Fisher's exact test. Discussion and compared age-associated gene expressions patterns in these cohorts and also compared them with 1 disease-associated gene expression.
3
Our work suggests an intimate intertwined relationship between aging and disease in their gene regulations. 4 We have shown that "healthy" and "common" aging shared a large proportion of genes, suggesting the 5 existence of a core aging program regardless of the individual's health status. This is not surprising, since 6 our "healthy" cohort was a subset of the "common" aging cohort. For genes whose expression in disease 7 individuals are not dramatically different from the "healthy" aging cohort (particularly for the direction of 8 gene expression regulation), adding these disease individuals to the "healthy" individuals will unlikely 9 change the overall gene expression pattern. In addition, we found our core aging genes were enriched for 10 candidate human age genes recorded in GenAge. Therefore, this core aging program likely reflects the main 11 aging regulation in humans since it is insensitive to the health status of the individuals enrolled for a 12 particular aging study.
14
Despite the large overlap between "healthy" and "common" aging genes, HSAGs and CSAGs showed 15 different function enrichment, and CAGs/CSAGs showed higher enrichment for disease genes. For example,
16
CAGs and CSAGs in subcutaneous fat and tibial artery were enriched for genes related to 17 neurodegenerative disease ( Supplemental Table S12 ). It is of note that aging genes in adipose and artery 
23
Disease associated gene expression regulations are overall different from age-associated genes, supporting 24 that aging and disease are fundamentally distinct and depend on different gene regulations. However, 25 disease associated transcriptome signatures do share some common genes with "healthy" aging signatures.
26
For these shared genes, the direction of gene regulation in "healthy" aging is largely consistent with the regulation direction induced by disease. This suggests that transcriptome regulation in healthy aging could 1 facilitate the development of disease. For example, even in the "healthy" aging adipose tissues, we observed 2 elevated inflammation gene expression (e.g., CDKN2A, IL4R, TGFB1 and PTPN22 expression in CAGs, 3 and TNFS4F expression in the HSAGs), and it has been noticed that obesity-associated chronic low-grade 4 inflammation is responsible for the decrease of insulin sensitivity (Chen et al. 2015 ), suggesting that age-5 associated gene regulation could facilitate the development of certain age-related diseases. 6 7 In contrast to the "common" aging signatures which were enriched for disease genes, HSAGs (particularly 8 the up-regulated HSAGs) were less enriched for disease genes and showed different associated functions.
9
For example, down-regulated CAGs in subcutaneous fat were overrepresented for disease traits like 10 cholesterol and hypertriglyceridemia; while down-regulated HSAGs were strongly related to HDL 11 cholesterol-triglycerides ("good" cholesterol). HSAGs also showed strong enrichment for genes related to 12 ribosome and RNA processing; previous studies have reported that both caloric restriction and rapamycin 13 treatment extend health/life-span but substantially decrease mRNA levels of ribosomal proteins through 14 reduced mTOR activity (Frenk and Houseley 2018) , therefore that HSAGs may regulate the ribosomal 15 proteins for the benefit of healthy tissue aging. 16 
17
We speculated that some "healthy-specific" aging genes provide protective mechanisms to prevent the 18 development of diseases. Using adipose tissue as an example, we found that the top few up-regulated genes 
26
while abiogenesis is known to be reduced in elderly individuals and correlates with the deteriorated 1 functions of old adipose tissues (Kirkland et al. 2002) . It could be an important feature for the healthy aging 2 program to up-regulate multiple protective genes to strengthen the resilience in these aging tissues. 3 4 We pointed out that one limitation of our study resides in how we defined a "healthy" aging cohort. It may 5 be argued that our definition of the "healthy" aging cohort is not truly healthy and better criteria should be 6 used. Although we fully understand and agree on this point, we are limited by the available samples in the 7 current GTEx release. When the full version GTEx data become available in near future, we expect to have 8 a sample size that we can define a healthier "healthy" aging cohort. On the other hand, it has been and will 9 continue to be difficult to collect tissues from a truly healthy living person as aging is normally accompanied 10 by various kinds of diseases and only less than 20% of older individuals are considered really healthy.
11
Previous studies focused on "healthy" aging used peripheral blood samples from a living cohort (Lunnon specific consideration was taken, most of these studies did not require that samples were from absolutely 16 healthy individuals. Therefore, we consider it is acceptable to define the "healthy" cohort as donors without 17 tissue-specific diseases given the resources available to us now, particularly as meaningful results seem to 18 be obtainable by this approach. 19 20 In conclusion, we performed a comparative analysis of "healthy" and "common" aging genes based on 21 transcriptomic data from GTEx. We found "common" aging signatures are comparably more associated 22 with genes and pathways that cause disorders during aging process, while "healthy" aging is likely to 23 contain more "good" factors and pathways that engage in boosting the systems resilience in humans. As a 24 future direction, a useful effort would be to catalog the protective aging gene expression regulations in 25 details and discover potential interventions to promote the healthy aging program in "common" aging 26 populations. Table S1 ). Details about the RNA-seq data are provided in the Supplemental Table S2 . for the start of the GTEx procedure). Tissue collection was completed within 24hrs of cardiac cessation.
23
Throughout the text we have used the term Post-Mortem Interval (PMI) to refer to sample ischemic time.
24
For 13 brain subregions provided by GTEx, only brain cerebellum and brain cortex have sample ischemic 25 time information. In those cases, we used donor ischemic time for the rest of the brain subregions, and they 26 are marked with specific notations. Negative PMI values observed in whole-blood samples were 1 transformed to 0 in the regression analysis (Supplemental Fig. S2b,c considered as an extra covariates in the second regression model (equation 2),  is the error term,  ,  , 21  ,  , is the regression coefficient for each variates. For each gene j, a least square approach was used to 22 estimate the regression coefficients. If  was significantly deviated from 0, gene j was then considered to 23 be an age-associated gene. Gene j with  > 0 was considered as up-regulated with age, gene j with  < 0 24 was considered as down-regulated with age.
25
Differential expression between the "disease" and "healthy" individuals 1 For differentially expression analysis we used the statistical methods implemented in the limma-voom 2 (Ritchie et al. 2015) package. We started by building a matrix with gene read counts in donors with tissue-3 specific diseases and donors without tissue-specific diseases ( Supplemental Table S7 ). Genes are kept if 4 they are expressed in at least two samples. We created a design matrix taking into account 2 conditions (e.g.
5
"disease" cohort and "healthy" cohort) and several covariates: 14 was used to perform GO classification. We first extracted gene symbols from each age-associated gene sets: 15 "common-specific aging genes, "core-aging genes" and "healthy-specific aging genes. These gene lists 16 were then submitted to DAVID by choosing GO_FAT and KEGG pathway terms to describe the 17 overrepresented functional terms for them. The threshold for overrepresented GO terms was set to FDR 18 less than 0.05.
20
Assembly of disease gene list and identify significant overlap between disease and aging genes 21 Disease genes were retrieved from two sources: NIH Genome-Wide Association Studies (GWAS) Catalog 22 and OMIM (Online Mendelian Inheritance in Man). We only considered genes in the GWAS catalog with 23 p-value < 510 -8 , a widely accepted threshold for genome-wide significance. Clustering and manual 24 curation were used to merge genes in GWAS and OMIM. We only considered disease categories which 25 contained with at least 5 genes. We then performed a Hypergeometric based test between the disease genes 1 and three age-associated gene sets in four tissues. Aging genes with FDR  0.01 were used for testing age-2 disease overlap enrichment (p-values less than 0.01 were considered significant). In addition, we separated 3 each gene set into up and down-regulated with age. To visualize the result, we selected the top 10 most 4 significant diseases in each tissue, which resulted in 75 unique diseases for down-regulated and 74 unique 5 diseases for up-regulated age-associated genes. P-value was then -log10 transformed and plotted in Fig Author contributions 17 Z.T. conceived and designed the project; L.Z. performed the analysis; L.Z. and Z.T. wrote the paper; J.Y., 18 S.P., J.Z., B.Z., and Y.S. contributed to the discussion of the results and helped revise the paper. All
